Cytokine-based immunotherapy, including interleukin 2 (IL-2) and recombinant human interferon-alpha 2a (IFN-α2a), is the first approved immunotherapy for renal cell carcinoma. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.